Related Experiment Videos
Treatment of congestive heart failure--state of the art and future trends
1Department of Cardiology, Moffitt/Long Hospital, San Francisco.
Insights
This review discusses cardiac failure management, highlighting lifestyle changes, diuretics, and vasodilators like ACE inhibitors. It also explores other agents and drugs that may prevent myocardial damage progression for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiac failure is a complex clinical syndrome diagnosed via imaging or hemodynamics.
- It stems from systolic or diastolic dysfunction, often co-occurring, necessitating etiological investigation for correctable causes.
Purpose of the Study:
- To review current and emerging therapeutic strategies for managing cardiac failure.
- To evaluate the efficacy and limitations of various pharmacological and non-pharmacological interventions.
Main Methods:
- Review of existing literature on cardiac failure treatments.
- Analysis of pharmacological agents including diuretics, digitalis, vasodilators, inotropic agents, and newer drug classes.
- Consideration of non-pharmacological approaches and their role.
Main Results:
- Non-pharmacological methods and diuretics form baseline therapy.
- Angiotensin-converting enzyme (ACE) inhibitors show efficacy in improving symptoms and survival.
- Other agents like phosphodiesterase inhibitors and beta-1-partial adrenoceptor agonists have mixed results, with potential for arrhythmias.
- Beta-adrenoceptor antagonists and calcium channel blockers show promise in preventing myocardial damage progression.
Conclusions:
- Cardiac failure management requires a multi-faceted approach, combining lifestyle modifications with targeted pharmacological therapies.
- ACE inhibitors are key in improving outcomes, while ongoing research focuses on agents preventing further myocardial damage.
Abstract:
1. Cardiac failure is a clinical syndrome of symptoms and signs, which can be confirmed by imaging or invasive haemodynamic techniques. It may be caused by systolic or diastolic dysfunction, but systolic dysfunction rarely occurs alone. It is important to ascertain the degree to which each contributes, and the precise aetiology of the condition, particularly in relation to surgically correctable lesions. 2. Non-pharmacological approaches including weight loss, salt restriction and lifestyle changes may be beneficial in some patients, and diuretics, which reduce the load on the heart, are the traditional baseline therapy. 3. Digitalis has been used where problems with contractility predominate, but its beneficial effect has been disputed, and expectations of improvement in patients in sinus rhythm should not be too high. 4. Vasodilators have been considered as the next line of treatment. Arteriolar dilators tend to increase cardiac output, but have little effect on pulmonary artery wedge pressure, and venodilators tend to have the opposite effect. Probably both actions are necessary and angiotensin converting enzyme (ACE) inhibitors, which have both, have proved effective in terms of symptoms and survival. 5. Various other inotropic agents have been tried. Phosphodiesterase inhibitors improve exercise tolerance, but may increase the probability of serious arrhythmias, already a significant cause of sudden death. beta 1-partial adrenoceptor agonists such as xamoterol have shown some promise, and anti-arrhythmic therapy has also been considered. 6. Drugs which prevent progression of myocardial damage would prove a great advance, and beta-adrenoceptor antagonists and calcium channel blockers appear to have considerable potential in this area.